IRIDEX Corporation  

(Public, NASDAQ:IRIX)   Watch this stock  
Find more results for IRIX
7.16
+0.13 (1.85%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.97 - 7.27
52 week 6.41 - 11.28
Open 7.25
Vol / Avg. 6,727.00/36,984.00
Mkt cap 71.81M
P/E 7.46
Div/yield     -
EPS 0.96
Shares 10.03M
Beta 1.12
Inst. own 58%
Oct 28, 2015
Q3 2015 IRIDEX Corp Earnings Release (Estimated) Add to calendar
Aug 6, 2015
Q2 2015 IRIDEX Corp Earnings Call - 5:00PM EDT - Add to calendar
Aug 6, 2015
Q2 2015 IRIDEX Corp Earnings Release - 4:00PM EDT - Add to calendar
Jun 3, 2015
IRIDEX Corp at LD Micro Invitational Conference
May 19, 2015
IRIDEX Corp at UBS Global Healthcare Conference
May 7, 2015
Q1 2015 IRIDEX Corp Earnings Call - Webcast
May 7, 2015
Q1 2015 IRIDEX Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Apr '15) 2015
Net profit margin 2.28% 23.45%
Operating margin 3.73% 6.04%
EBITD margin - 7.02%
Return on average assets 2.35% 26.59%
Return on average equity 2.91% 33.69%
Employees 106 -
CDP Score - -

Address

1212 Terra Bella Ave
MOUNTAIN VIEW, CA 94043-1824
United States - Map
+1-650-9404700 (Phone)
+1-650-9404710 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company's ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes. In addition, the Company's ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation. The Company offers ophthalmology treatments for a number of conditions, such as Age-related Macular Degeneration, Diabetic Retinopathy, Proliferative, Glaucoma, Retinal Tears and Detachments, Retinopathy of Prematurity, Ocular Tumors and Macular Holes.

Officers and directors

Will M. Moore Jr. Chairman of the Board, Interim President and Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
James H. Mackaness Chief Financial Officer, Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Ronald T. Steckel Vice President - Operations
Age: 62
Bio & Compensation  - Reuters
George R. Marcellino PhD Director
Age: 66
Bio & Compensation  - Reuters
Scott A. Shuda Director
Age: 49
Bio & Compensation  - Reuters
Sanford Fitch Independent Director
Age: 74
Bio & Compensation  - Reuters
Ruediger Naumann-Etienne Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters